Scientific Publications
and Presentations

Innovation and discovery drive our business. We are proud to share publications and presentations about our products and investigational pipeline candidates.

Please Select Year

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ, VISION Investigators. N Engl J Med (2021).

Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics

Rahbar K, Bodei L, Morris MJ. J Nucl Med. (2019), pp 1504-1506.

Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumours: A systematic review and meta-analysis

Strosberg J, Leeuwenkamp O, Siddiqui MK. Cancer Treat Rev. (2021), 102141

Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review

Watson C, Tallentire CW, Ramage JK, Srirajaskanthan R, Leeuwenkamp O, Fountain D. World J Gastroenterol. (2020), pp 3686-3711.

MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68 Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

Gruber L, Jiménez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, Schoenberg SO, Reindl R, Orlandi F, Mariani M, Jaschke W, Virgolini I. J Nucl Med. (2020), pp 1749-1755.

Safety, tolerability and clinical implementation of ‘ready-to-use’ 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Manoharan P, Lamarca A, Navalkissoor S, Calero J, Chan PS, Julyan P, Sierra M, Caplin M, Valle J. ESMO Open (2020).

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-DOTATATE: an analysis of the NETTER-1 study

Strosberg J, Kunz PL et al. on behalf of the NETTER-1 study group. Eur J Nucl Med Mol Imaging. (2020), pp 2372-2382

Radiation Safety Observations Associated with 177Lu Dotatate Patients

Nelson KL, Sheetz MA. Health Phys. (2019), pp 680-687.

Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. J Nucl Med. (2019), pp 910-916.

NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, Lindsay S, Metz DC, Pryma DA, Stabin MG, Strosberg JR. J Nucl Med. (2019), pp 937-943.

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Hennrich U, Kopka K. Pharmaceuticals. (2019).

Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis

Saravana-Bawan B, Bajwa A, Paterson J, McEwan AJB, McMullen TPW. Clin Nucl Med. (2019), pp 719-727.

Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors

Kendi AT, Halfdanarson TR, Packard A, Dundar A, Subramaniam RM. AJR Am J Roentgenol. (2019), pp 309-317.

Quality of life in patients with midgut NET following peptide receptor radionuclide therapy

Marinova M, Mücke M, Fischer F, Essler M, Cuhls H, Radbruch L, Ghaei S, Conrad R, Ahmadzadehfar H. Eur J Nucl Med Mol Imaging. (2019).

Caring for Patients Receiving 177Lu-DOTATATE, Lutathera®: A Treatment of Hope for Patients With Gastroenteropancreatic Neuroendocrine Tumors

Hromadik LK, Sturges L. J. Radiol. Nurs. (2019).